The Latest Breaking News from BMY

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.

Bristol-Myers Squibb is set to release its third-quarter results by the end of this month, and analysts expect a notable double-digit drop in earnings.